Non-canonical peptides presented on MHC molecules as possible biomarkers for (immune)therapies.

Abstract

Recent advances in neoantigen research have accelerated the development and approval of tumor (immune)therapies, particularly antibody-based treatments for solid tumors. Neoantigens, arising from tumor-specific changes such as genomic mutations, dysregulated RNA splicing, and post-translational modifications, are newly formed antigens in tumor cells. The identification and prediction of these neoantigens have been facilitated by advancements in next-generation sequencing (NGS) and bioinformatic